ArticleBritish journal of clinical pharmacology2026
Impact of secured prescription implementation on ambulatory pregabalin use in France: A regional assessment in the French Nouvelle-Aquitaine.
Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of secured prescription implementation on ambulatory pregabalin use in France: A regional assessment in the French Nouvelle-Aquitaine.British journal of clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe French authorities mandated the use of secure prescriptions for pregabalin on May 2021. This study aimed to evaluate the impact of this measure on pregabalin use and misuse in Nouvelle-Aquitaine, a southwestern French region with around six million inhabitants.
methodsThis study was performed from the Nouvelle-Aquitaine regional databases of the French healthcare insurance system. It included all individuals who received at least one pregabalin reimbursement between 24 May 2020 and 24 May 2022. We analysed changes in the prevalence and incidence of pregabalin use and misuse, as well as the characteristics of pregabalin users. Misuse was defined as use exceeding 600 mg/day or engaging in doctor or pharmacy shopping. Two time periods were considered: 24 May 2020-23 May 2021 and 24 May 2021-24 May 2022.
resultsThe implementation of secured prescriptions led to a 16.9% [16.5; 17.3] decrease in pregabalin prevalent use and in a 36.6% [36.1; 37.1] decrease in pregabalin incident use. Additionally, pregabalin misuse reduced by 7.7% [7.0; 8.4] for prevalent misuse and 71.5% [69.3; 73.6] for incident one. Most users were women aged over 60. Patients' characteristics changed between the two periods. Use of psychotropic and opioid treatment increased in prevalent users.
conclusionsThe introduction of secured prescription forms was associated with a marked reduction in pregabalin use and misuse in Nouvelle-Aquitaine, especially in incident misuse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.